Michael B. Atkins
Impact in
- Oncology top 0.01%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cutaneous Melanoma Detection and Management
- Immunology top 0.02%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
Papers in
- Oncology 242
- Cancer Immunotherapy and Biomarkers 135
- CAR-T cell therapy research 88
- Cutaneous Melanoma Detection and Management 54
-
- Renal cell carcinoma treatment 162
- Co-authors
- David F. McDermott (118 shared papers)John M. Kirkwood (34 shared papers)Arthur J. Sober (8 shared papers)Geoffrey Thomas Gibney (14 shared papers)James Walter Mier (53 shared papers)Janice P. Dutcher (33 shared papers)John F. Thompson (13 shared papers)Brian I. Rini (42 shared papers)
- Journals
- Journal of Clinical Oncology (61 papers)Clinical Cancer Research (42 papers)Annals of Oncology (35 papers)Journal for ImmunoTherapy of Cancer (34 papers)Journal of Immunotherapy (24 papers)
- Partner nations
- United StatesUnited KingdomFrance
In The Last Decade
Michael B. Atkins
506 papers receiving 74.9k citations
Michael B. Atkins's Hit Papers
Peers
Comparison fields: 5 of 181
- Oncology 41.8k
- Immunology 19.3k
- Pulmonary and Respiratory Medicine 20.4k
- Cancer Research 7.9k
- Molecular Biology 20.0k
Countries citing papers authored by Michael B. Atkins
This map shows the geographic impact of Michael B. Atkins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael B. Atkins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael B. Atkins more than expected).
Fields of papers citing papers by Michael B. Atkins
This network shows the impact of papers produced by Michael B. Atkins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael B. Atkins. The network helps show where Michael B. Atkins may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael B. Atkins, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 521 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer Hit paper breakdown → | 2012 | 10591 |
| 2 | Final Version of 2009 AJCC Melanoma Staging and Classification Hit paper breakdown → | 2009 | 3801 |
| 3 | Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Hit paper breakdown → | 2018 | 2972 |
| 4 | Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2019 | 2634 |
| 5 | Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma Hit paper breakdown → | 2001 | 2186 |
| 6 | Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System Hit paper breakdown → | 2001 | 1977 |
| 7 | Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2019 | 1971 |
| 8 | Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab Hit paper breakdown → | 2014 | 1961 |
| 9 | Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma Hit paper breakdown → | 2017 | 1783 |
| 10 | Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study Hit paper breakdown → | 2009 | 1737 |
| 11 | High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993 Hit paper breakdown → | 1999 | 1693 |
| 12 | Predictive biomarkers for checkpoint inhibitor-based immunotherapy Hit paper breakdown → | 2016 | 1379 |
| 13 | Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain Hit paper breakdown → | 2018 | 1038 |
| 14 | Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma Hit paper breakdown → | 2018 | 1011 |
| 15 | Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial Hit paper breakdown → | 2019 | 817 |
| 16 | Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma Hit paper breakdown → | 2004 | 799 |
| 17 | Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Hit paper breakdown → | 1997 | 741 |
| 18 | Arginase-Producing Myeloid Suppressor Cells in Renal Cell Carcinoma Patients: A Mechanism of Tumor Evasion Hit paper breakdown → | 2005 | 708 |
| 19 | 2004 | 703 | |
| 20 | Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55 Hit paper breakdown → | 1994 | 701 |
About Michael B. Atkins
Michael B. Atkins is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Immunology, Cancer Research and Molecular Biology, having authored 521 papers that have together received 77.2k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (162 papers), Cancer Immunotherapy and Biomarkers (135 papers), CAR-T cell therapy research (88 papers), Immunotherapy and Immune Responses (63 papers), Melanoma and MAPK Pathways (60 papers), Cutaneous Melanoma Detection and Management (54 papers), Renal and related cancers (41 papers) and Cancer Genomics and Diagnostics (38 papers). The work is most often cited by research in Oncology (41.8k citations), Immunology (19.3k citations), Pulmonary and Respiratory Medicine (20.4k citations), Cancer Research (7.9k citations) and Molecular Biology (20.0k citations). Michael B. Atkins has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include David F. McDermott, John M. Kirkwood, Arthur J. Sober, Geoffrey Thomas Gibney, James Walter Mier, Janice P. Dutcher, John F. Thompson, Brian I. Rini, Kelly M. McMasters and Daniel G. Coit. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Annals of Oncology, Journal for ImmunoTherapy of Cancer and Journal of Immunotherapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.